Lactobacillus acidophilus Improves Intestinal Inflammation in an Acute Colitis Mouse Model by Regulation of Th17 and Treg Cell Balance and Fibrosis Development
Restricted accessResearch articleFirst published online March, 2018
Lactobacillus acidophilus Improves Intestinal Inflammation in an Acute Colitis Mouse Model by Regulation of Th17 and Treg Cell Balance and Fibrosis Development
Disruption of the balance among the microbiota, epithelial cells, and resident immune cells in the intestine is involved in the pathogenesis of inflammatory bowel disease (IBD). Probiotics exert protective effects against IBD, and probiotic commensal Lactobacillus species are common inhabitants of the natural microbiota, especially in the gut. To investigate the effects of Lactobacillus acidophilus on the development of IBD, L. acidophilus was administered orally in mice with dextran sodium sulfate (DSS)-induced colitis. DSS-induced damage and the therapeutic effect of L. acidophilus were investigated. Treatment with L. acidophilus attenuated the severity of DSS-induced colitis. Specifically, it suppressed proinflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor-α, IL-1β, and IL-17 in the colon tissues, which are produced by T helper (Th) 17 cells. Moreover, in vitro L. acidophilus treatment directly induced T regulatory (Treg) cells and the production of IL-10, whereas the production of IL-17 was suppressed in splenocytes. In addition, we found that L. acidophilus treatment decreased the levels of α-smooth muscle actin, a marker of activated myofibroblasts, and type I collagen compared with control mice. These results suggest that L. acidophilus may be a novel treatment for IBD by modulating the balance between Th17 and Treg cells, as well as fibrosis development.
Get full access to this article
View all access options for this article.
References
1.
PodolskyDK: Inflammatory bowel disease. N Engl J Med, 2002; 347:417–429.
2.
XavierRJ, PodolskyDK: Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007; 448:427–434.
Van AsscheG, GeboesK, RutgeertsP: Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis, 2004; 10:55–60.
5.
SpecaS, GiustiI, RiederF, LatellaG: Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol, 2012; 18:3635–3661.
6.
FiocchiC, LundPK: Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol, 2011; 300:G677–G683.
7.
GalvezJ: Role of Th17 Cells in the pathogenesis of human IBD. ISRN Inflamm, 2014; 2014:928461.
8.
BoumaG, StroberW: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol, 2003; 3:521–533.
9.
LiuZJ, YadavPK, SuJL, WangJS, FeiK: Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol, 2009; 15:5784–5788.
10.
OwagaE, HsiehRH, MugendiB, MasukuS, ShihCK, ChangJS: Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. Int J Mol Sci, 2015; 16:20841–20858.
11.
HolttaV, KlemettiP, SaloHM, et al.: Interleukin-17 immunity in pediatric Crohn's disease and ulcerative colitis. J Pediatr Gastroenterol Nutr, 2013; 57:287–292.
12.
UenoA, JijonH, ChanR, et al.: Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis, 2013; 19:2522–2534.
13.
SahinA, CalhanT, CengizM, et al.: Serum interleukin 17 levels in patients with Crohn's disease: Real life data. Dis Markers, 2014; 2014:690853.
14.
ItoR, KitaM, Shin-YaM, et al.: Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun, 2008; 377:12–16.
15.
ZhangZ, ZhengM, BindasJ, SchwarzenbergerP, KollsJK: Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis, 2006; 12:382–388.
16.
MaulJ, LoddenkemperC, MundtP, et al.: Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology, 2005; 128:1868–1878.
17.
Gomes-SantosAC, MoreiraTG, Castro-JuniorAB, et al.: New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin Dev Immunol, 2012; 2012:560817.
18.
ShiboletO, KarmeliF, EliakimR, et al.: Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis, 2002; 8:399–406.
19.
GuarnerF, MalageladaJR: Gut flora in health and disease. Lancet, 2003; 361:512–519.
20.
ChenL, ZouY, PengJ, et al.: Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23/Th17 axis. J Immunol Res, 2015; 2015:909514.
21.
SuzukiK, SunX, NagataM, et al.: Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium. Pathol Int, 2011; 61:228–238.
22.
HamamotoN, MaemuraK, HirataI, MuranoM, SasakiS, KatsuK: Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol, 1999; 117:462–468.
23.
ZhangL, ZhaoY: The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: Multiple pathways on the road. J Cell Physiol, 2007; 211:590–597.
ParvezS, MalikKA, Ah KangS, KimHY: Probiotics and their fermented food products are beneficial for health. J Appl Microbiol, 2006; 100:1171–1185.
28.
StantonC, GardinerG, MeehanH, et al.: Market potential for probiotics. Am J Clin Nutr, 2001; 73:476S–483S.
29.
LiAL, MengXC, DuanCC, HuoGC, ZhengQL, LiD: Suppressive effects of oral administration of heat-killed Lactobacillus acidophilus on T helper-17 immune responses in a bovine beta-lactoglobulin-sensitized mice model. Biol Pharm Bull, 2013; 36:202–207.
30.
RoselliM, FinamoreA, NuccitelliS, et al.: Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes. Inflamm Bowel Dis, 2009; 15:1526–1536.
31.
FicheraA, LovadinaS, RubinM, CiminoF, HurstRD, MichelassiF: Patterns and operative treatment of recurrent Crohn's disease: A prospective longitudinal study. Surgery, 2006; 140:649–654.
32.
LiuY, ZhuH, SuZ, et al.: IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCbeta/Erk1/2/NF-kappaB-dependent signaling pathway. Int Immunol, 2012; 24:605–612.
33.
OkamotoY, HasegawaM, MatsushitaT, et al.: Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum, 2012; 64:3726–3735.
34.
ValenteAJ, YoshidaT, GardnerJD, SomannaN, DelafontaineP, ChandrasekarB: Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal, 2012; 24:560–568.
